62.95 +0.06 (0.09%)
After hours: 4:11PM EDT
|Bid||18.44 x 100|
|Ask||69.91 x 200|
|Day's Range||62.08 - 64.07|
|52 Week Range||45.31 - 75.36|
|PE Ratio (TTM)||-43.95|
|Earnings Date||Oct 26, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||60.17|
Jim Cramer sat down with Clay Siegall, the co-founder, chairman and CEO of Seattle Genetics, to hear more about his company's pipeline.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one at risk of being "Amazon-ed."
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / Both Akari Therapeutics and Seattle Genetics saw their shares climb higher on Wednesday after the companies had encouraging news about clinical trials. While ...
Seattle Genetics launched to its highest point in four months on a series of cancer drug trials with Merck and Astellas Pharma.
Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Seattle Genetics, Inc. today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer . SGN-LIV1A is an investigational antibody-drug conjugate that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, ovarian, and cervical cancers.
TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations. In addition, there are no FDA-approved therapies for patients who progress following CPI treatment," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor therapy.
Genmab A/S and Seattle Genetics, Inc. announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Seattle Genetics, Inc. announced today that it will report its third quarter financial results on Thursday, October 26, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.
Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced final data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma were published in the journal Blood.
Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.